Fecal Calprotectin Level Reflects the Severity of Clostridium difficile Infection

Jieun Kim, M.D.1, Heejung Kim, M.D.1, Hyun Ju Oh, M.T.1, Hyung Sun Kim, B.S.1, Youn Jee Hwang, B.S.2, Dongeun Yong, M.D.1, Seok Hoon Jeong, M.D.1, and Kyungwon Lee, M.D.1

Department of Laboratory Medicine and Research Institute of Bacterial Resistance1; Brain Korea 21 PLUS Project for Medical Science2, Yonsei University College of Medicine, Seoul, Korea

Clostridium difficile is a significant nosocomial and community-acquired pathogen, and is the leading cause of antibiotic-induced diarrhea associated with high morbidity and mortality. Given that the treatment outcome depends on the severity of C. difficile infection (CDI), we aimed to establish an efficient method of assessing severity, and focused on the stool biomarker fecal calprotectin (FC). FC directly reflects the intestinal inflammation status of a patient, and can aid in interpreting the current guidelines, which requires the integration of indirect laboratory parameters. The distinction of 80 patients with CDI versus 71 healthy controls and 30 severe infection cases versus 50 mild cases was possible using FC as a marker. The area under the receiver operating characteristic curves were 0.821 and 0.746 with a sensitivity of 75% and 70% and specificity of 79% and 80%, for severe versus mild cases, respectively. We suggest FC as a predictive marker for assessing CDI severity, which is expected to improve the clinical management of CDI.

Key Words: Clostridium difficile infection, Fecal calprotectin, Severity assessment

INTRODUCTION

Clostridium difficile is a significant nosocomial and community-acquired pathogen, and is the leading cause of antibiotic-induced diarrhea [1, 2]. C. difficile infection (CDI) diagnosis currently relies on clinical manifestations of diarrhea, fever, abdominal pain, and leukocytosis, supported by laboratory confirmation of toxigenic C. difficile in the stool or colonoscopic findings consistent with pseudomembranous colitis (PMC). CDI is associated with high morbidity and mortality, thus, to improve CDI management and clinical outcome, several guidelines have been suggested as factors to help define severe CDI, including patients’ age, body temperature, serum albumin level, and peripheral white blood cell count [3-6]. However, the proposed severity assessments have limitations, and not all recommended laboratory findings are readily accessible, making comprehensive integration difficult. Moreover, monitoring CDI after initiating therapy is often necessary, especially when a patient is treated with vancomycin. However, concerns exist regarding the risk of prolonged vancomycin use, which would exert selection pressure to promote the colonization and transmission of vancomycin-resistant enterococci and increase systemic side effects in patients with renal failure [7].

Recently, non-invasive fecal biomarkers that reflect intestinal inflammation were identified, and their CDI diagnostic values were evaluated [8]. Fecal lactoferrin, a fecal material derived from neutrophils, has been shown to correlate with CDI severity [9]. In addition, mRNA of C-X-C motif chemokine 5 (CXCL-5) and mRNA and protein of interleukin (IL)-8 correlated with clinical outcome [10], whereas positive guaiac-based fecal occult blood (FOB) showed low sensitivity in diagnosing CDI [11]. However, except for FOB, the previously investigated biomarkers are...
not currently available for in vitro diagnostic use in Korea, and only fecal calprotectin (FC) level is currently used for examining intestinal inflammation [12].

FC, a 36.5-kDa molecule derived from the cytoplasm of neutrophils, mononuclear cells, and squamous epithelial cells, indicates the inflammatory status of the intestinal lumen [13]. The role of FC was examined in many other gastrointestinal diseases such as inflammatory bowel disease (IBD), acute gastroenteritis, and malignancies [14]. The use of FC in CDI diagnosis was also demonstrated in a few studies; however, this marker showed restricted utility for assessing CDI severity [11, 15]. We investigated demographics of subjects according to severity of CDI and demonstrated the diagnostic value of FC to determine its potential as an alternative biomarker for monitoring CDI severity.

METHODS

1. Subjects
Seventy-one healthy control subjects and 80 CDI subjects were randomly selected for this retrospective study. Subjects were recruited among patients whose stool samples were requested for routine fecal immunochemical test in medical examinations and for C. difficile culture, respectively, between March and October of 2015. This study was conducted at a University tertiary referral hospital in Seoul, South Korea, and it was approved by the Institutional Review Board of Severance Hospital. The demographics of subjects were assessed by reviewing hospital records and laboratory results (Table 1).

2. Definitions
Since FC level can be increased under some circumstances [16], subjects without possible intestinal inflammation were selected as healthy controls. CDI patients were strictly defined by the presence of symptoms, usually including diarrhea, and a positive test for toxigenic C. difficile culture as determined by GeneXpert C. difficile PCR assay (Cepheid, Sunnyvale, CA, USA) and toxin B PCR.

CDI patients were divided into mild and severe groups based on a severity assessment score developed by Zar et al [6]. Patients with a score of ≥2 were considered to have severe CDI. One point each was given for age of >60 yr, body temperature >38.3°C, albumin level <25 g/L, or peripheral white blood cell count >15×10^9 cells/L within 48 hr of enrollment. In the case of endoscopic evidence of PMC or treatment in the intensive care unit, patients were considered to have severe CDI.

Table 1. Baseline characteristics of patients with Clostridium difficile infection according to disease severity

| Characteristics                        | Mild disease (n = 50) | Severe disease (n = 30) | P value |
|----------------------------------------|-----------------------|-------------------------|---------|
| Male                                    | 21 (42)               | 11 (37)                 | 0.637   |
| Age, median (yr)                       | 59 (range, 49-73)     | 71 (range, 60-79)       | 0.025   |
| >60 yr of age                          | 23 (46)               | 22 (73)                 | 0.017   |
| Received antibiotic therapy prior to onset of CDI | 44 (88)               | 26 (86)                 | 1.000   |
| Received antibiotic therapy within 14 days prior to onset of CDI | 41 (82)               | 24 (80)                 | 0.824   |
| Underlying diseases                    |                       |                         |         |
| Cardiovascular disease and/or hypertension | 27 (54)               | 17 (57)                 | 0.816   |
| Malignancy                             | 17 (34)               | 12 (40)                 | 0.589   |
| Chronic respiratory disease            | 6 (12)                | 6 (20)                  | 0.351   |
| Diabetes mellitus                      | 9 (18)                | 8 (27)                  | 0.359   |
| Renal failure                          | 12 (24)               | 12 (40)                 | 0.131   |
| Factors associated with disease severity |                       |                         |         |
| Hospitalized in the ICU                | 1 (2)                 | 4 (13)                  | 0.063   |
| Body temperature > 38.3°C              | 3 (6)                 | 8 (30)                  | 0.042   |
| Serum albumin level < 25 g/L           | 1 (2)                 | 8 (27)                  | 0.002   |
| WBC count > 15×10^9 cells/L            | 1 (2)                 | 8 (27)                  | 0.002   |
| Presence of pseudomembranous colitis   | 2 (5)                 | 4 (13)                  | 0.394   |
| Fecal calprotectin (μg/g)              | 188.2 (41.4-591.6)    | 1,391.5 (range, 173.5-2,075.9) |         |

Abbreviations: CDI, Clostridium difficile infection; WBC, white blood cell count; ICU, intensive care unit.
unit, 2 points were given.

3. Measurement of FC
FC was measured in a single frozen stool sample from all subjects by using a commercially available ELISA kit: Calprotectin Bühlmann ELISA (Bühlmann Laboratories AG, Schönenbuch, Switzerland). Experimental samples were assayed with the standards and controls included with the kit according to the manufacturer’s instructions. The supernatants were diluted 3-fold if a higher concentration was expected.

4. Statistical analyses
Statistical analyses were performed by using SPSS software (version 23.0; SPSS Inc., Chicago, IL, USA). Means of normally distributed quantitative values in more than two groups were compared by one-way analysis of variance, whereas non-normally distributed quantitative values were compared by using the Kruskal-Wallis test. Non-parametric tests were used to determine whether clinical characteristics differed between the mild CDI group and severe CDI group, including the Mann-Whitney U test, Pearson’s chi-square test, and Fisher’s exact test. A two-tailed value of $P<0.05$ was considered statistically significant.

ROC curve was analyzed to identify the optimal cut-off values for our study.

RESULTS

1. Characteristics of CDI patients
Among the 80 CDI subjects enrolled in the study, 50 had mild CDI and 30 had severe CDI. Baseline characteristics are shown in Table 1. There was no statistically significant difference in the history of antibiotic therapy between the two groups or in specific underlying diseases.

2. Diagnostic accuracy of FC and cut-off values according to CDI severity
The median FC level was significantly higher (1,391.5 μg/g; interquartile range [IQR]=173.5-2,075.9 μg/g) in the severe CDI group than in the mild CDI group (188.2 μg/g; IQR=41.4-591.6 μg/g) ($P<0.001$). The area under the ROC curve (AUC) was 0.746 for CDI severity with an optimum FC value of 729.8 μg/g, sensitivity of 70%, and specificity of 80% between severe CDI and mild CDI cases. The AUC was 0.821 for CDI diagnosis, with an optimum FC value of 112.5 μg/g, sensitivity of 75%, and specificity of 79% between severe CDI and mild CDI cases (Fig. 1).

FC concentrations were higher ($P<0.001$) in the 30 severe CDI patients (median, 1,391.5 μg/g; IQR, 170.0-2,088.1 μg/g) than in the 50 mild CDI patients (median, 188.2 μg/g; IQR, 41.4-188.2 μg/g), and both were higher than those of the healthy controls.

**Fig. 1.** ROC curve analysis of fecal calprotectin concentrations in *Clostridium difficile* infection (CDI) cases and healthy controls. (A) The area under the ROC curve (AUC) is 0.746 (95% confidence interval [CI], 0.626-0.866) in severe CDI vs mild CDI; (B) The AUC is 0.821 (95% CI, 0.755-0.887) in CDI vs healthy controls.
controls (median, 35.6 μg/g; IQR, 10.7-108.9 μg/g) (P = 0.019 and P < 0.001 for mild CDI and severe CDI, respectively) (Fig. 2).

**DISCUSSION**

Careful consideration is essential when changing antibiotic regimens, and prompt and objective evidence can guide appropriate therapy [17]. However, many approaches currently used in the laboratory diagnosis of CDI are time-consuming and costly, providing limited information on disease severity [18]. According to the current guidelines, when initiating antibiotic therapy is necessary, oral metronidazole is recommended in cases of non-severe CDI and vancomycin is recommended for severe or refractory CDI [4]. Therefore, it is important to confirm infection severity with a reliable biomarker, which can in turn serve as a guide for selecting antibiotic regimens that best reflect CDI status. This objective assessment would allow for improved patient care to overcome the current limitations of continuous monitoring and to reduce side effects and the potential for therapeutic resistance.

The diagnostic significance of FC has been assessed in many gastrointestinal disorders, and its concentration in healthy subjects is generally below 50 μg/g [19], which was concordant with the levels of the subjects included in our study. However, FC concentrations have been reported to be as high from 994 mg/L [11] to about 2,000 μg/g [15]. Eleven CDI patients (13.8% of the 80 patients) in this study had high FC concentrations (over 2,000 μg/g), including one patient with a level of 6,000 μg/g who had a total severity score of 3 points, with persistent watery diarrhea and fulminant PMC. These findings indicate greater intestinal inflammation, which may reflect the significant morbidity and mortality associated with severe CDI.

Previous studies have shown the diagnostic utility of FC in CDI, in which the patients’ status was confirmed by a combination of toxin ELISA, quantitative PCR, or toxigenic C. difficile culture, which differs from the more accurate practice of CDI diagnosis routinely performed in our hospital, where the diagnosis is made by toxigenic C. difficile culture, GeneXpert C. difficile PCR assay, and toxin B PCR [15, 20]. Furthermore, to verify the diagnostic significance of FC, we strictly excluded patients and healthy controls with gastrointestinal disorders other than CDI, which can influence FC levels.

Here, we demonstrated that FC significantly correlated with CDI severity and could effectively discriminate among severe CDI, mild CDI, and healthy controls. FC showed a particularly strong ability to distinguish CDI patients from healthy controls according to the respectable AUC value, higher sensitivity, and high specificity.

There are currently no guidelines concerning the use of fecal biomarkers for estimating CDI severity. Fecal biomarkers have been proposed and widely studied as potential non-invasive alternatives in IBD research; however, potential biomarkers that can serve as indicators of disease and disease stratification are also needed to more effectively direct CDI treatment. We suggest FC as a predictive marker for assessing CDI severity, which is expected to improve the clinical management of this condition.

**Authors’ Disclosures of Potential Conflicts of Interest**

No potential conflicts of interest relevant to this article were reported.

**REFERENCES**

1. Kim YA, Rim JH, Choi MH, Kim H, Lee K. Increase of Clostridium difficile in community; another worrisome burden for public health. Ann Clin Microbiol 2016;19:7-12.
2. Poutanen SM and Simor AE. Clostridium difficile-associated diarrhea in adults. CMAJ 2004;171:51-8.
3. Cohen SH, Gerdin DN, Johnson S, Kelly CP, Loo VG, McDonald LC, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 2010;31:431-55.
4. Debast SB, Bauer MP, Kuijper EJ. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect 2014;20(S2):S1-26.

5. Surawicz CM, Brandt LJ, Binion DG, Ananthakrishnan AN, Curry SR, Gilligan PH, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 2013;108:478-98; quiz 499.

6. Zar FA, Bakkanagari SR, Moorath KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007;45:302-7.

7. Aradhya S, Manian FA, Hafidh SA, Bhutto SS, Alpert MA. Significant absorption of oral vancomycin in a patient with Clostridium difficile colitis and normal renal function. South Med J 2006;99:518-20.

8. Kim H, Kim WH, Kim M, Jeong SH, Lee K. Evaluation of a rapid membrane enzyme immunoassay for the simultaneous detection of glutamate dehydrogenase and toxin for the diagnosis of Clostridium difficile infection. Ann Lab Med 2014;34:235-9.

9. Boone JH, DiPersio JR, Tan MJ, Salstrom SJ, Wickham KN, Carman RJ, et al. Elevated lactoferrin is associated with moderate to severe Clostridium difficile disease, stool toxin, and 027 infection. Eur J Clin Microbiol Infect Dis 2013;32:1517-23.

10. El Feghaly RE, Stauber JL, Deych E, Gonzalez C, Tarr PI, Haslam DB. Markers of intestinal inflammation, not bacterial burden, correlate with clinical outcomes in Clostridium difficile infection. Clin Infect Dis 2013;56:1713-21.

11. Shastri YM, Berghs D, Povse N, Sfâfâr V, Shastri S, Weindel M, et al. Prospective multicenter study evaluating fecal calprotectin in adult acute bacterial diarrhea. Am J Med 2008;121:1099-106.

12. Lee KM. Fecal biomarkers in inflammatory bowel disease. Intest Res 2013;11:73-8.

13. Steinbakk M, Naess-Andresen CF, Lingaas E, Dale I, Brandtzaeg P, Fagerhol MK. Antimicrobial actions of calcium binding leucocyte L1 protein, calprotectin. Lancet 1990;336:763-5.

14. Caccaro R, D’Incà R, Sturniolo GC. Clinical utility of calprotectin and lactoferrin as markers of inflammation in patients with inflammatory bowel disease. Expert Rev Clin Immunol 2010;6:551-8.

15. Whitehead SJ, Shipman KE, Cooper M, Ford C, Gama R. Is there any value in measuring faecal calprotectin in Clostridium difficile positive faecal samples? J Med Microbiol 2014;63:590-3.

16. van Rheenen PF, Van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ 2010;341:c3396.

17. Leekha S, Terrell CL, Edson RS. General principles of antimicrobial therapy. Mayo Clin Proc 2011;86:156-67.

18. Crobach MJ, Dekkers OM, Wilcox MH, Kuijper EJ. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): data review and recommendations for diagnosing Clostridium difficile-infection (CDI). Clin Microbiol Infect 2009;15:1053-66.

19. Waugh N, Cummins E, Royle P, Kandala NB, Shyangdan D, Arasaradnam R, et al. Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation. Health Technol Assess 2013;17:xv-xix, 1-211.

20. Swale A, Miyajima F, Roberts P, Hall A, Little M, Beadsworth MB, et al. Calprotectin and lactoferrin faecal levels in patients with Clostridium difficile infection (CDI): a prospective cohort study. PLoS One 2014;9:e106118.